Filing Flows › Ovid Therapeutics (OVID) › Q4 2024
Ovid Therapeutics (OVID) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Ovid Therapeutics (OVID) reported revenue of $76K for the fourth quarter 2024 (Q4 2024), -46% from a year earlier and -56% from the quarter before.
Ovid Therapeutics, Q4 2024: revenue $76K (-46% year over year), net loss $9.3M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $76K | -56% | -46% |
| Operating profit | −$10.7M | — | — |
| Net earnings | −$9.3M | — | — |
| Operating cash flow | −$10.0M | — | — |
What changed
Revenue was $76K in Q4 2024, down 46% year over year and down 56% from the previous quarter.
Operating costs exceeded revenue by $10.7M, an operating margin of -14107.9%. Total costs fell 41% while revenue fell 46%. The quarter ended with a net loss of $9.3M, narrower than the previous quarter's $14.0M loss.
Operating cash flow was −$10.0M. Non-cash charges added back $160K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $2.2M. Capital expenditures of $22K exceeded it, leaving free cash flow of −$10.0M.
Questions
What was Ovid Therapeutics' revenue in the fourth quarter 2024?
Ovid Therapeutics (OVID) reported revenue of $76K for the fourth quarter 2024 (Q4 2024), -46% from a year earlier and -56% from the quarter before.
Source: Ovid Therapeutics 10-K on SEC EDGAR.